Knowledge Action Portal on NCDs

1 Resources
Short
<!-- THEME DEBUG --> <!-- THEME HOOK: 'field' --> <!-- FILE NAME SUGGESTIONS: ▪️ field--node--title--news-and-events.html.twig ✅ field--node--title.html.twig ▪️ field--node--news-and-events.html.twig ▪️ field--title.html.twig ▪️ field--string.html.twig ▪️ field.html.twig --> <!-- 💡 BEGIN CUSTOM TEMPLATE OUTPUT from 'themes/custom/whokap/templates/field/field--node--title.html.twig' --> MPP signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia <!-- END CUSTOM TEMPLATE OUTPUT from 'themes/custom/whokap/templates/field/field--node--title.html.twig' -->

02 Sep 2024

Medicines Patent Pool

MPP signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia

On the side lines of the World Cancer Congress 2022, the Medicines Patent Pool (MPP) announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least...

02 Sep 2024

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Read More